A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 452
- 试验地点
- 546
- 主要终点
- To Determine and Compare the Frequency and Severity of Adverse Events as Assessed by CTCAE Version 3.0 for the Regimens Administered on This Study.
研究概览
简要总结
This randomized phase III trial studies the side effects of paclitaxel when given together with cisplatin or topotecan with or without bevacizumab and to compare how well they work in treating patients with stage IVB, cervical cancer that has come back or is persistent. Drugs used in chemotherapy, such as paclitaxel, cisplatin, and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether paclitaxel is more effective when given together with cisplatin or topotecan with or without bevacizumab in treating patients with cervical cancer.
详细描述
PRIMARY OBJECTIVES:
I. To determine whether the addition of bevacizumab to chemotherapy improves overall survival. Also to determine if a regimen involving paclitaxel and topotecan improves overall survival in comparison to a regimen involving cisplatin and paclitaxel. These regimens are to be evaluated in patients with stage IVB, recurrent, or persistent carcinoma of the cervix.
II. To determine and compare the frequency and severity of adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 for the regimens administered on this study.
SECONDARY OBJECTIVES:
I. To estimate and compare the progression-free survival of patients treated by the regimens investigated on this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients must have primary stage IVB, recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy
- •All patients must have measurable disease; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each lesion must be >= 20 mm when measured by conventional techniques, including palpation, plain x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), or >= 10 mm when measured by spiral CT; biopsy confirmation is required if the lesion(s) measures < 30 mm or if the treating physician determines it is clinically indicated; patients must have at least one "target lesion" to be used to assess response on this protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST); this lesion should be the one that was biopsied if one was performed; tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
- •Absolute neutrophil count (ANC) >= 1500/mcl
- •Platelets >= 100,000/mcl
- •Serum creatinine =< upper limit of normal (ULN) (Common Toxicity Criteria [CTC] grade 0) or calculated creatinine clearance (Jeliffe formula) >= 60 ml/min
- •Bilirubin =< 1.5 x institutional normal
- •Serum glutamic oxaloacetic transaminase (SGOT) =< 2.5 x institutional normal
- •Alkaline phosphatase =< 2.5 x institutional normal
- •Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thrombo-embolus)
- •Partial thromboplastin time (PTT) < 1.2 times the upper limit of normal
- •Urine protein-creatinine ratio (UPC ratio) < 1.0
- •Patients must have a GOG performance status of 0 or 1
- •Patients must have recovered from the effects of surgery, radiation therapy, or chemoradiotherapy; at least six weeks must have elapsed from the last administration of chemoradiotherapy, and at least three weeks must have elapsed from the last administration of radiation therapy alone; at least six weeks must have elapsed from the time of any major surgical procedure prior to randomization
- •Patients must have signed an approved informed consent and authorization permitting release of personal health information
- •Patients must meet all of the pre-entry requirements, including baseline QOL questionnaire
- •Patients must be free of active infection requiring antibiotics
排除标准
- •Patients with bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage
- •Patients previously treated with chemotherapy except when used concurrently with radiation therapy
- •Patients who have received concurrent paclitaxel and/or concurrent topotecan with radiation therapy are ineligible
- •Patients with craniospinal metastases
- •Patients with a concomitant malignancy other than non-melanoma skin cancer
- •Patients with a prior invasive malignancy (except non-melanoma skin cancer) who have had any evidence of disease within the last 5 years or whose prior malignancy treatment contraindicates the current protocol therapy
- •Patients with serious non-healing wound, ulcer, or bone fracture; this includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess for which an interval of 3 to 6 months must pass before study entry; in addition, the patient must have undergone correction (or spontaneous healing) of the perforation/fistula and/or the underlying process causing the fistula/perforation; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
- •Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
- •Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study
- •Patients with clinically significant cardiovascular disease; this includes:
- •Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg
- •Myocardial infarction or unstable angina < 6 months prior to registration
- •New York Heart Association (NYHA) grade II or greater congestive heart failure
- •Serious cardiac arrhythmia requiring medication; this does not include asymptomatic, atrial fibrillation with controlled ventricular rate
- •CTCAE grade 2 or greater peripheral vascular disease (at least brief [< 24 hours (hrs)]) episodes of ischemia managed non-surgically and without permanent deficit)
- •History of CVA within six months
- •Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
- •Patients with or with anticipation of invasive procedures as defined below:
- •Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of bevacizumab therapy
- •Major surgical procedure anticipated during the course of the study; this includes, but is not limited to abdominal surgery (laparotomy or laparoscopy) prior to disease progression, such as colostomy or enterostomy reversal, interval or secondary cytoreductive surgery, or second look surgery; please consult with the study chair prior to patient entry for any questions related to the classification of surgical procedures
- •Core biopsy, within 7 days prior to randomization
- •Patients who are pregnant or nursing; bevacizumab should not be administered to pregnant women; bevacizumab should not be administered to nursing women; patients of childbearing potential must agree to use contraceptive measures during study therapy and for at least six months after completion of bevacizumab therapy
- •Patients who have received prior therapy with any anti-vascular endothelial growth factor (VEGF) drug, including bevacizumab
- •Patients with clinical symptoms or signs of gastrointestinal obstruction and who require parenteral hydration and/or nutrition
- •Patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study; the investigator should feel free to consult the Study Chair or Study Co-Chairs for uncertainty in this regard
- •Patients with significant peripheral vascular disease
- •Patients with pre-existing grade 2 or greater peripheral neuropathy
研究组 & 干预措施
Arm I (paclitaxel and cisplatin)
Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV on day 1 or 2.
干预措施: Cisplatin (Drug)
Arm I (paclitaxel and cisplatin)
Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV on day 1 or 2.
干预措施: Laboratory Biomarker Analysis (Other)
Arm I (paclitaxel and cisplatin)
Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV on day 1 or 2.
干预措施: Paclitaxel (Drug)
Arm I (paclitaxel and cisplatin)
Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV on day 1 or 2.
干预措施: Quality-of-Life Assessment (Other)
Arm I (paclitaxel and cisplatin)
Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV on day 1 or 2.
干预措施: Questionnaire Administration (Other)
Arm II (paclitaxel, cisplatin, bevacizumab)
Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV and bevacizumab IV over 30-90 minutes on day 1 or 2.
干预措施: Bevacizumab (Biological)
Arm II (paclitaxel, cisplatin, bevacizumab)
Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV and bevacizumab IV over 30-90 minutes on day 1 or 2.
干预措施: Cisplatin (Drug)
Arm II (paclitaxel, cisplatin, bevacizumab)
Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV and bevacizumab IV over 30-90 minutes on day 1 or 2.
干预措施: Laboratory Biomarker Analysis (Other)
Arm II (paclitaxel, cisplatin, bevacizumab)
Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV and bevacizumab IV over 30-90 minutes on day 1 or 2.
干预措施: Paclitaxel (Drug)
Arm II (paclitaxel, cisplatin, bevacizumab)
Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV and bevacizumab IV over 30-90 minutes on day 1 or 2.
干预措施: Quality-of-Life Assessment (Other)
Arm II (paclitaxel, cisplatin, bevacizumab)
Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV and bevacizumab IV over 30-90 minutes on day 1 or 2.
干预措施: Questionnaire Administration (Other)
Arm III (topotecan hydrochloride and paclitaxel)
Patients receive paclitaxel IV over 3 hours on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
干预措施: Laboratory Biomarker Analysis (Other)
Arm III (topotecan hydrochloride and paclitaxel)
Patients receive paclitaxel IV over 3 hours on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
干预措施: Paclitaxel (Drug)
Arm III (topotecan hydrochloride and paclitaxel)
Patients receive paclitaxel IV over 3 hours on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
干预措施: Quality-of-Life Assessment (Other)
Arm III (topotecan hydrochloride and paclitaxel)
Patients receive paclitaxel IV over 3 hours on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
干预措施: Questionnaire Administration (Other)
Arm III (topotecan hydrochloride and paclitaxel)
Patients receive paclitaxel IV over 3 hours on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
干预措施: Topotecan Hydrochloride (Drug)
Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab)
Patients receive paclitaxel IV over 3 hours and bevacizumab IV over 30-90 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
干预措施: Bevacizumab (Biological)
Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab)
Patients receive paclitaxel IV over 3 hours and bevacizumab IV over 30-90 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
干预措施: Laboratory Biomarker Analysis (Other)
Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab)
Patients receive paclitaxel IV over 3 hours and bevacizumab IV over 30-90 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
干预措施: Paclitaxel (Drug)
Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab)
Patients receive paclitaxel IV over 3 hours and bevacizumab IV over 30-90 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
干预措施: Quality-of-Life Assessment (Other)
Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab)
Patients receive paclitaxel IV over 3 hours and bevacizumab IV over 30-90 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
干预措施: Questionnaire Administration (Other)
Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab)
Patients receive paclitaxel IV over 3 hours and bevacizumab IV over 30-90 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
干预措施: Topotecan Hydrochloride (Drug)
结局指标
主要结局
To Determine and Compare the Frequency and Severity of Adverse Events as Assessed by CTCAE Version 3.0 for the Regimens Administered on This Study.
时间窗: From date of enrollment until 30 days after treatment completion
The number of patients on each arm who have Grade 3 AE or higher toxicity.
Overall Survival
时间窗: From entry into the study to death or the date of last contact, assessed up to 5 years
The observed length of life from randomization into the study to death or the date of last contact.
Progression-free Survival
时间窗: From study entry until disease progression, death or date of last contact, assessed up to 5 years (During treatment: every 3 weeks if by physical exam, every 6 weeks by CXR, CT or MRI. In follow-up: quarterly for 2 years then semi-annually for 3 years)
Disease that can be assessed clinically (physical examination) should be evaluated every cycle (every 3 weeks). Disease assessed by imaging modalities (CXR, CT, MRI) should be evaluated every other cycle unless other evidence of a change mandates earlier assessment. Tumor measurements should also be done after the final cycle (if the patient is taken off of study therapy for a reason other than progression) and then every 3 months x 2 years (followed with every 6 months x 3 years) until progression is documented. "Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions assessed radiographically and 50% increase if the only target lesion is a solitary pelvic mass measured by physical exam, or unequivocal progression of a non-target lesion, or the appearance of new lesions", or similar definition as accurate and appropriate.
Tumor Response
时间窗: Every cycle (if assessed by physical exam), every other cycle (if assessed by imaging), after the final cycle, then every 3 months x 2 years, then every 6 months x 3 years up to 5 years.
Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>= 30% decrease in the sum of the longest diameter of target lesions by CT, MRI or CXR. If the only target lesion is a solitary pelvic mass measured by physical exam, which is not radiographically measurable, a 50% increase in longest diameter is required; Overall Response (OR) = CR + PR.
次要结局
未报告次要终点